



Mauna Kea Technologies Continues New York Area Momentum with Cellvizio® Placement at The Mount Sinai Hospital

New York Society of Gastroenterology (NYSGE) and Icahn School of Medicine at Mount Sinai to Host Educational Program for Gastroenterologists Highlighting Confocal Laser Endomicroscopy

Paris, France and Cambridge, MA, USA, September 12, 2016 - Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the placement of a Cellvizio System at The Mount Sinai Hospital in New York, NY, which is ranked seventh in the nation for Gastroenterology and GI Surgery. This represents the 14th Cellvizio System in the New York metro area, highlighting strong adoption among leading hospitals and academic centers in the largest U.S. market.

“Adding Cellvizio to our armamentarium is key to ensure that we continue to offer our patients leading-edge medical technologies,” said Christopher J. DiMaio, MD, Associate Professor and Director of Therapeutic Endoscopy at The Mount Sinai Hospital. “With the help of endomicroscopy, we can perform real-time, non-invasive evaluation of GI tissues during interventional procedures on patients suffering from pancreatic and biliary diseases, as well as more general GI disorders. As a consequence, we believe that we will be able to reduce our level of indetermination during our everyday endoscopic examinations and therapeutic procedures, which is one of our key objectives in order to improve patient care while eliminating unnecessary procedures.”

On September 8, 2016, the New York Society for Gastrointestinal Endoscopy (NYSGE) hosted an educational program titled “Gastric Cancer and Pre-Neoplastic Lesions of the Stomach” at the Icahn School of Medicine at Mount Sinai, that discussed the use of confocal laser endomicroscopy (CLE) during a presentation on current and new diagnostic modalities for pre-neoplastic gastric lesions and early gastric cancer. David Carr-Locke, MD, Professor of Gastroenterology at the Icahn School of Medicine at Mount Sinai and Chief of the Division of Digestive Diseases at Mount Sinai Beth Israel, delivered the presentation, titled “Through the Looking Glass: Advanced Diagnostic Imaging for High Risk Lesions.”

Dr. Carr-Locke, one of the world’s most experienced Cellvizio users, commented, “We look forward to partnering with NYSGE and our local colleagues to support the continuing education of gastroenterologists and GI fellows in the management of gastric cancer and pre-neoplastic lesions of the stomach. This program, covering the unique benefits of confocal laser endomicroscopy as an advanced diagnostic tool for patients with these disorders, is opportune given The Mount Sinai Hospital’s recent acquisition of a Cellvizio system. We have been using Cellvizio for many years at Mount Sinai Beth Israel for this and other applications.”

Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies, added, “We are pleased to bring the Cellvizio system to The Mount Sinai Hospital, which further highlights the growing adoption of CLE among leading institutions in the United States. With the recent endorsement by the American Society of General Surgeons and the white paper from the American Gastroenterological Association, we have reasons to be confident that both the adoption and the utilization of Cellvizio will continue to accelerate in the near future.”

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 13, 2016 under number R.16-054 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial



markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements.

This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.

Mauna Kea Technologies

Benoit Jacheet
CFO
investors@maunakeatech.com

United States

Zack_Kubow / Lee Roth
The Ruth Group
646-536-7020 / 7012
zkubow@theruthgroup.com /
lroth@theruthgroup.com

U.S. Media

Christopher Hippolyte
The Ruth Group
646-536-7023
chippolyte@theruthgroup.com

France and Europe

NewCap - Investor
Relations
Florent Alba
+33 (0)1 44 71 94 94
maunakea@newcap.fr